Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Actinic keratosis modelling in mice: A translational study.
Pillon A, Gomes B, Vandenberghe I, Cartron V, Cèbe P, Blanchet JC, Sibaud V, Guilbaud N, Audoly L, Lamant L, Kruczynski A. Pillon A, et al. Among authors: audoly l. PLoS One. 2017 Jun 29;12(6):e0179991. doi: 10.1371/journal.pone.0179991. eCollection 2017. PLoS One. 2017. PMID: 28662116 Free PMC article.
Endotrophin, a Key Marker and Driver for Fibroinflammatory Disease.
Henriksen K, Genovese F, Reese-Petersen A, Audoly LP, Sun K, Karsdal MA, Scherer PE. Henriksen K, et al. Among authors: audoly lp. Endocr Rev. 2024 May 7;45(3):361-378. doi: 10.1210/endrev/bnad036. Endocr Rev. 2024. PMID: 38091968 Review.
Towards a consensus definition of immune exclusion in cancer.
Tiwari A, Oravecz T, Dillon LA, Italiano A, Audoly L, Fridman WH, Clifton GT. Tiwari A, et al. Among authors: audoly l. Front Immunol. 2023 Mar 22;14:1084887. doi: 10.3389/fimmu.2023.1084887. eCollection 2023. Front Immunol. 2023. PMID: 37033994 Free PMC article. Review.
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, Katzmann G, Christian HJ, Andersen N, Allersdorfer A, Olwill SA, Meibohm B, Audoly LP, Swinkels DW, van Swelm RPL. Hohlbaum AM, et al. Among authors: audoly lp. Br J Pharmacol. 2018 Apr;175(7):1054-1065. doi: 10.1111/bph.14143. Epub 2018 Feb 23. Br J Pharmacol. 2018. PMID: 29329501 Free PMC article.
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA. Terwisscha van Scheltinga AG, et al. Among authors: audoly l. J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10. J Nucl Med. 2014. PMID: 24614223 Free article.
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.
Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. Olwill SA, et al. Among authors: audoly l. Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3. Mol Cancer Ther. 2013. PMID: 24002935
60 results